Please login to the form below

Not currently logged in

DH invites proposals for genetics funding

DH and the Wellcome Trust are inviting proposals from organisations and research groups for funding from the Health Innovation Challenge Fund

The Department of Health (DH) and the Wellcome Trust are inviting proposals from organisations and research groups seeking to draw on funding from the Health Innovation Challenge Fund. 'Advancing Genetic Discoveries into Clinical Practice' is the first area of expertise to be offered funding, with up to £20m.

Medical genetics is the first of a number of areas that the Health Innovation Challenge Fund will offer funding for. The aim of the cash injection is to help capitalise on the wealth of information created by human genome analysis and to bring the emerging insights to clinical application. The Health Innovation Challenge Fund can support initiatives for up to five years and has a total of up to £100m available, contributed in equal measure by the DH and the Wellcome Trust.

The purpose of the Health Innovation Challenge Fund is to facilitate high-quality technological developments that can deliver economic and patient health benefits and build on the UK's excellence in science. The initiative will stimulate the delivery of technologies, products and interventions having clinical applicability within the NHS.

20th July 2009

From: Healthcare


Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...